Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v2.3.0.15
Segment Information
 9 Months Ended
Sep. 30, 2011
SEGMENT INFORMATION [Abstract]  
Segment Reporting Disclosure [Text Block]
12.
SEGMENT INFORMATION
The accounting policies of the segments are described in Note 1 of the Company’s audited consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2010.  Corporate charges are allocated to each of the reporting segments on the basis of total salary expense. Corporate charges include corporate headquarters costs and certain depreciation expenses. Certain corporate capital expenditures have not been allocated from the Sales Services segment to the other reporting segments since it is impracticable to do so.
On August 1, 2011 the Company announced the formation of its new business unit, Interpace BioPharma. Interpace BioPharma provides biopharmaceutical clients with full-service product commercialization solutions. These services include full supply chain management, operations, sales, marketing, compliance, and regulatory/medical management. The initial revenue and costs associated with this unit are reflected in the Product Commercialization Services segment for both the three- and nine-month periods ended September 30, 2011.

 
Sales
Services
 
Marketing
Services
 
Product Commercialization Services
 
Consolidated
Three months ended September 30, 2011:
 
 
 
 
 
 
 
Revenue
$
29,267

 
$
5,129

 
$
2,850

 
$
37,246

Operating income (loss)
$
539

 
$
(875
)
 
$
368

 
$
32

Capital expenditures
$
59

 
$
26

 
$
—

 
$
85

Depreciation expense
$
375

 
$
93

 
$
2

 
$
470

 
 
 
 
 
 
 
 
Three months ended September 30, 2010:
 
 
 

 
 

 
 

Revenue
$
33,292

 
$
2,680

 
$
—

 
$
35,972

Operating income (loss)
$
627

 
$
(207
)
 
$
—

 
$
420

Capital expenditures
$
512

 
$
—

 
$
—

 
$
512

Depreciation expense
$
249

 
$
12

 
$
—

 
$
261

 
 
 
 
 
 
 
 
Nine months ended September 30, 2011:
 
 
 

 
 

 
 

Revenue
$
106,207

 
$
14,233

 
$
3,534

 
$
123,974

Operating income (loss)
$
2,576

 
$
(5,188
)
 
$
452

 
$
(2,160
)
Capital expenditures
$
178

 
$
156

 
$
—

 
$
334

Depreciation expense
$
1,111

 
$
287

 
$
2

 
$
1,400

 
 
 
 
 
 
 
 
Nine months ended September 30, 2010:
 
 
 

 
 

 
 

Revenue
$
91,937

 
$
8,015

 
$
—

 
$
99,952

Operating loss
$
(1,247
)
 
$
(484
)
 
$
—

 
$
(1,731
)
Capital expenditures
$
1,536

 
$
—

 
$
—

 
$
1,536

Depreciation expense
$
729

 
$
44

 
$
—

 
$
773